研究员、博导,医药生物技术国家重点实验室
地址:南京市仙林校区仙林大道163号,210023
邮箱:lupeng.ye@nju.edu.cn
研究领域 |
基因编辑和肿瘤免疫治疗
工作经历 |
2010-2015,浙江大学 博士
2015-2016,浙江大学 博士后
2017-2021,耶鲁大学医学院 博士后
2021-2022,耶鲁大学医学院 副研究科学家
2022-至今,南京大学现代生物研究院 助理教授 特聘研究员 博导
荣誉奖励 |
2022,国家级海外青年人才计划
2022,江苏特聘教授
杂志任职 |
2022-至今,Frontiers in Genome Editing - Associate Editor
2022-至今,Frontiers in Genetics - Guest Associate Editor
代表性成果 |
[1] Ye L, Lam S, Yang L, Suzuki K, Zou Y, Lin Q, Zhang Y, Clark P, Peng L, Chen S†. AAV-mediated delivery of a Sleeping-Beauty transposon and an mRNA-encoded transposase for the engineering of therapeutic immune cells.Nature Biomedical Engineering. 2023. doi.org/10.1038/s41551-023-01058-6
[2] Ye L*, Park JJ*, Peng L*, Yang Q *, Chow RD, Dong M, Lam S, Guo J, Tang E, Zhang Y, Wang G, Dai X, Du Y, Kim H, Cao H, Errami Y, Clark P, Bersenev A, Montgomery RR, Chen S†. A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. Cell Metabolism. 2022.doi.org/10.1016/j.cmet.2022.02.009.
[3] Ye L*, Park JJ*, Dong MB*, Yang Q, Chow RD, Peng L, Du Y, Guo J, Dai X, Wang G, Errami Y, Chen S†. In vivo CRISPR screening in CD8 T cells with AAV-Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma. Nature Biotechnology. 2019. doi: 10.1038/s41587-019-0246-4.
[4] Dong MB*, Wang G*, Chow RD*, Ye L*, Zhu L, Dai X, Park JJ, Kim HR, Errami Y, Guzman CD, Zhou X, Chen KY, Renauer PA, Du Y, Shen J, Lam SZ, Zhou JJ, Lannin DR, Herbst RS, Chen S†. Systematic Immunotherapy Target Discovery Using Genome-Scale In vivo CRISPR Screens in CD8 T Cells. Cell. 2019. doi: 10.1016/j.cell.2019.07.044. (*Contributed equally)
[5] Chow RD*, Wang G*, Ye L*, Codina A, Kim HR, Shen L, Dong MB, Errami Y, Chen S†. In vivo profiling of metastatic double knockouts through CRISPR-Cpf1 screens. Nature Methods. 2019. doi: 10.1038/s41592-019-0371-5. (*Contributed equally)
[6] Ye L*, Wang C*, Hong L, Sun N, Chen D, Chen S†, Han F†. Programmable DNA repair with CRISPRa/i enhanced homology-directed repair efficiency with a single Cas9. Cell Discovery. 2018 Jul 24;4:46. doi:10.1038/s41421-018-0049-7. (*Contributed equally)
[7] Renauer P, Park JJ, Bai M, Acosta A, Lee W, Lin G, Zhang Y, Dai X, Wang G, Errami Y, Wu T, Clark P, Ye L†, Yang Q†, Sidi Chen†. Immunogenetic metabolomics revealed key enzymes that modulate CAR-T metabolism and function. Cancer Immunology Research. 2023. doi: 10.1158/2326-6066.CIR-22-0565. (Corresponding Author)
[8] Park JJ*, Codina A*, Ye L*, Lam S, Guo J, Clark P, Zhou X, Peng L, Chen S†. Double knockout CRISPR screen for cancer resistance to T cell cytotoxicity. Journal of Hematology & Oncology. 15, 172 (2022). (*Contributed equally)
[9] Hong, L, Ye, L†. The interferon-γ receptor pathway: a new way to regulate CAR T cell-solid tumor cell adhesion. Signal Transduction and Targeted Therapy. 7, 315 (2022). (Corresponding Author)
[10] Hong L, Li N, Gasque V, Mehta S, Ye L, Wu Y, Li J, Gewies A, Ruland J, Hirschi K, Eichmann A, Hendry C, Dijk D, Mani A†. Prdm6 controls heart development by regulating neural crest cell differentiation and migration. JCI Insight. 2022;7(4):e156046.https://doi.org/10.1172/jci.insight.156046.
团队风采 |